Benzinga | Mar 1, 2021 12:19PM EST

Canaccord Genuity Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $91

Canaccord Genuity maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $95 to $91.